No Data
Yakkang Biotech: Yakang Biotech Report for the Third Quarter of 2024
Yakkang Biotech Report for the Third Quarter of 2024
Yao Kang Biology (688046.SH): Achieved net income of 98.2144 million yuan in the first three quarters.
Pharmaron (688046.SH) announced on October 30th that the company achieved revenue of 0.51 billion yuan in the first three quarters of 2024, a year-on-year increase of 12.13%; the net income attributable to the shareholders of the listed company was 98.2144 million yuan, a year-on-year decrease of 16.57%, with a basic earnings per share of 0.24 yuan.
Shareholder Qingdao Guoyao of Yaokang Biological (688046.SH) reduced its shareholding by 0.8882 million shares, decreasing its stake to 5%.
Yao Kang Biology (688046.SH) announced that on September 24, 2024, the shareholder Qingdao National Pharmaceutical Daichuang ...
We Think That There Are More Issues For GemPharmatech (SHSE:688046) Than Just Sluggish Earnings
YaoKang Biotech (688046.SH): Cumulative repurchase of 0.3712% of the company's shares.
On September 2nd, GeLongHui announced that as of August 31st, 2024, the company has repurchased a total of 1,521,975 shares of the company through the Shanghai Stock Exchange trading system through centralized competitive bidding, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan per share, and the lowest price was 11.89 yuan per share. The total amount paid was RMB 23,862,462.57 (excluding stamp duty, transaction fees, and other trading costs).
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is LackingNo Data
No Data
